Chronic sunitinib treatment of RCC cell lines activates MET and AXL signaling, induces the epithelial-mesenchymal transition, and enhances cell migration, invasion, and angiogenesis [42, 43]. The gene discussed is MET; the disease is renal cell carcinoma.